- Home
- RXRX vs ADNT Comparison
RXRX vs ADNT Comparison
Compare RXRX & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | ADNT |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.6B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RXRX | ADNT |
|---|---|---|
| Price | $4.09 | $21.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 10 |
| Target Price | $7.50 | ★ $23.10 |
| AVG Volume (30 Days) | ★ 20.7M | 1.3M |
| Earning Date | 02-27-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $43,689,000.00 | ★ $14,535,000,000.00 |
| Revenue This Year | $6.74 | $1.86 |
| Revenue Next Year | $34.31 | $2.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $10.04 |
| 52 Week High | $12.36 | $26.16 |
Technical Indicators
Market Signals| Indicator | RXRX | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 50.65 |
| Support Level | $4.35 | $20.32 |
| Resistance Level | $4.74 | $21.95 |
| Average True Range (ATR) | 0.26 | 1.00 |
| MACD | -0.07 | -0.16 |
| Stochastic Oscillator | 9.37 | 21.22 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.